Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - imidacloprid - topical solution/suspension - imidacloprid guanidine active 100.0 g/l - parasiticides - dog - puppy | dog - small or toy | ferrets | rabbit | angora | bunny | dog - small | dog - toy | lop eared - dogbiting louse | dogsucking louse | flea - ctenocephalides spp. | flea - larvae (ctenocephalides spp.) | flea allergic dermatitis

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - imidacloprid - topical solution/suspension - imidacloprid guanidine active 100.0 g/l - parasiticides - cat - over 4 kg - flea - ctenocephalides spp. | flea - larvae (ctenocephalides spp.) | flea allergic dermatitis

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - imidacloprid - topical solution/suspension - imidacloprid guanidine active 100.0 g/l - parasiticides - cat - up to 4kg | kitten | young cat - flea | flea - ctenocephalides spp. | flea - larvae (ctenocephalides spp.) | flea allergic dermatitis | ctenocephalides spp. | ground fleas

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

resene paints (australia) limited - copper present as cuprous thiocyanate; copper present as cuprous thiocyanate; copper present as cuprous thiocyanate; copper present as cuprous thiocyanate; copper present as cuprous thiocyanate; zinc pyrithione; zinc pyrithione; zinc pyrithione; zinc pyrithione; zinc pyrithione - paint - copper present as cuprous thiocyanate cyanide active 226.0 g/l; copper present as cuprous thiocyanate cyanide active 228.0 g/l; copper present as cuprous thiocyanate cyanide active 247.0 g/l; copper present as cuprous thiocyanate cyanide active 247.0 g/l; copper present as cuprous thiocyanate cyanide active 251.0 g/l; zinc pyrithione mineral-zinc active 48.5 g/l; zinc pyrithione mineral-zinc active 49.5 g/l; zinc pyrithione mineral-zinc active 44.6 g/l; zinc pyrithione mineral-zinc active 48.5 g/l; zinc pyrithione mineral-zinc active 43.7 g/l - antifouling

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

advantage - imidacloprid(100g/l)+moxidectin(10g/l) - topical solution/suspension - insecticide,anthelmintic

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

advantage - imidacloprid(100g/l)+moxidectin(25g/l) - topical solution/suspension - insecticide,anthelmintic

United States - English - NLM (National Library of Medicine)

mwi - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), bacitracin zinc (unii: 89y4m234es) (bacitracin - unii:58h6rwo52i), hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - neomycin 3.5 mg in 1 g - neomycin and polymyxin b sulfates, bacitracin zinc, and hydrocortisone ophthalmic ointment is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye (see clinical pharmacology: microbiology). the particular anti-infective drugs in this product

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - citalopram hydrobromide (unii: i1e9d14f36) (citalopram - unii:0dhu5b8d6v) - citalopram 40 mg - citalopram tablets, usp are indicated for the treatment of depression. the efficacy of citalopram in the treatment of depression was established in 4 to 6 week; controlled trials of outpatients whose diagnosis corresponded most closely to the dsm-iii and dsm-iii-r category of major depressive disorder (see clinical pharmacology ). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. the antidepressant action of citalopram tablets, usp in hospitalized depressed patients has not been adequately studied. the efficacy

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - citalopram hydrobromide (unii: i1e9d14f36) (citalopram - unii:0dhu5b8d6v) - citalopram 40 mg - citalopram tablets, usp are indicated for the treatment of depression. the efficacy of citalopram in the treatment of depression was established in 4 to 6 week; controlled trials of outpatients whose diagnosis corresponded most closely to the dsm-iii and dsm-iii-r category of major depressive disorder (see clinical pharmacology). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. the antidepressant action of citalopram tablets, usp in hospitalized depressed patients has not been adequately studied. the efficacy

United States - English - NLM (National Library of Medicine)

mwi - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), bacitracin zinc (unii: 89y4m234es) (bacitracin - unii:58h6rwo52i), hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - neomycin 3.5 mg in 1 g - neomycin and polymyxin b sulfates, bacitracin zinc and hydrocortisone ophthalmic ointment is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye (see clinical pharmacology, microbiology). the particular anti-infective drugs in this product